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Abstract
Background
Studies have shown that airway obstruction and increased bronchial reactivity are present
in early life in children developing asthma, which challenges the dogma that airway inflam-
mation leads to low lung function. Further studies are needed to explore whether low lung
function and bronchial hyperreactivity are inherent traits increasing the risk of developing air-
way inflammation and asthmatic symptoms in order to establish timely primary preventive
initiatives.
Methods and findings
We investigated 367 (89%) of the 411 children from the at-risk Copenhagen Prospective
Studies on Asthma in Childhood 2000 (COPSAC2000) birth cohort born to mothers with
asthma, who were assessed by spirometry and bronchial reactivity to methacholine from
age 1 month, plethysmography and bronchial reversibility from age 3 years, cold dry air
hyperventilation from age 4 years, and exercise challenge at age 7 years. The COPSAC
pediatricians diagnosed and treated asthma based on symptom load, response to inhaled
corticosteroid, and relapse after treatment withdrawal according to a standardized algo-
rithm. Repeated measures mixed models were applied to analyze lung function trajectories
in children with asthma ever or never at age 1 month to 13 years. The number of children
ever versus never developing asthma in their first 13 years of life was 97 (27%) versus 270
(73%), respectively. Median age at diagnosis was 2.0 years (IQR 1.2–5.7), and median
remission age was 6.2 years (IQR 4.2–7.8). Children with versus without asthma had
reduced lung function (z-score difference, forced expiratory volume, −0.31 [95% CI −0.47;
−0.15], p < 0.001), increased airway resistance (z-score difference, specific airway resis-
tance, +0.40 [95% CI +0.24; +0.56], p < 0.001), increased bronchial reversibility (difference
in change in forced expiratory volume in the first second [ΔFEV1], +3% [95% CI +2%; +4%],
p < 0.001), increased reactivity to methacholine (z-score difference for provocative dose,
−0.40 [95% CI −0.58; −0.22], p < 0.001), decreased forced expiratory volume at cold dry air
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challenge (ΔFEV1, −4% [95% CI −7%; −1%], p < 0.01), and decreased forced expiratory vol-
ume after exercise (ΔFEV1, −4% [95% CI −7%; −1%], p = 0.02). Both airway obstruction
and bronchial hyperreactivity were present before symptom debut, independent of disease
duration, and did not improve with symptom remission. The generalizability of these findings
may be limited by the high-risk nature of the cohort (all mothers had a diagnosis of asthma),
the modest study size, and limited ethnic variation.
Conclusions
Children with asthma at some point at age 1 month to 13 years had airway obstruction and
bronchial hyperreactivity before symptom debut, which did not worsen with increased
asthma symptom duration or attenuate with remission. This suggests that airway obstruc-
tion and bronchial hyperreactivity are stable traits of childhood asthma since neonatal life,
implying that symptomatic disease may in part be a consequence of these traits but not their
cause.
Author summary
Why was this study done?
• It is believed that asthma develops from inflammation in the lungs that leads to loss of
lung function, but low lung function may be an inherent trait in children at risk of
asthma instead of a consequence of inflammation.
• It is important to explore whether low lung function is an inherent trait that increases
the risk of developing airway inflammation and asthma in order to establish primary
preventive initiatives for low lung function.
What did the researchers do and find?
• Ninety-seven children who developed asthma and 270 children without asthma from
the Danish COPSAC2000 birth cohort born to mothers with asthma were studied exten-
sively with longitudinal lung function measurements from age 1 month to 13 years.
• Lung function was measured by spirometry from age 1 month and plethysmography
from age 3 years, including assessments of bronchial reversibility to inhaled β2-agonist
from age 3 years. Bronchial reactivity was assessed by methacholine challenge from age
1 month, cold dry air hyperventilation from age 4 years, and exercise challenge at age 7
years.
• Children developing asthma had reduced lung function from age 1 month throughout
childhood compared to the children without asthma.
• The lung function deficit was present before the children developed asthma, did not
progress with symptoms, and remained even if symptoms ceased.
Lung function development in children with asthma
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What do these findings mean?
• Low lung function appears to begin in early childhood in a group of children who will
develop asthma. The lung function trait is established prior to development of airway
inflammation and asthma, and does not worsen with increased duration of asthma
symptoms. As airway obstruction and increased bronchial reactivity manifest as early as
1 month of age, it is possible that preventive measures undertaken during pregnancy
will be most effective.
Introduction
The current paradigm of asthma pathophysiology suggests that an inflammatory process in the
airways leads to progressive bronchial hyperreactivity and lung function deficits [1]. An alter-
native hypothesis is causality in the opposite direction, i.e., that reduced airway caliber and
bronchial hyperreactivity are inherent and stable traits that increase the risk of asthmatic
symptoms, exaggerated hyperreactivity, and intermittent airway obstruction from a superim-
posed inflammatory process. In support of this, anti-inflammatory inhaled corticosteroid
(ICS) treatment does not affect the natural course of lung function in children [2–6]. Further-
more, reticular basement membrane and airway smooth muscle thickness are unrelated to
inflammatory cell counts in bronchial biopsies [7]. This alternative causal direction from air-
way obstruction and bronchial hyperreactivity to asthma symptoms implies that prevention
must take place before symptom debut and maybe even before birth [8,9].
We aimed to study this alternative paradigm with rigorous prospective assessment of dis-
ease duration and remission. Spirometry and bronchial reactivity to methacholine were
assessed in neonates [10,11]. Neonatal spirometry was volume-anchored and therefore compa-
rable to repeated assessments of spirometry and bronchial reactivity during childhood [12–
15]. Effort-independent measures of airway resistance and measures of bronchial reactivity
were recorded until age 13 years.
Methods
This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guidelines (S1 STROBE Checklist).
The study was nested in Copenhagen Prospective Studies on Asthma in Childhood 2000
(COPSAC2000): a Danish prospective birth cohort study of 411 infants born during 1998–2001
to mothers with a history of asthma [16]. At enrollment at age 1 month, we excluded any child
with a history of symptoms of lower airway infection or neonatal mechanical ventilation, pre-
term birth (gestational age< 36 weeks), or any congenital abnormality or systemic illness. The
children were examined at half-yearly scheduled visits until age 7 years, and again at age 13
years, including assessments of lung function 11 times during childhood. Thus, longitudinal
lung function assessment during childhood was a strong and predefined focus of COPSAC2000,
which is detailed in the cohort baseline paper [16], but there was no prospective analysis plan
for how to model the data with respect to asthma development.
The local ethics committee (KF 01-289/96) and the Danish Data Protection Agency (2015-
41-3696) approved the study. Both parents gave oral and written informed consent before
enrollment.
Lung function development in children with asthma
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Lung function
Neonatal spirometry. Neonatal spirometry was performed at age 1 month by forced flow
volume measurements applying the volume-anchored raised volume rapid thoracoabdominal
compression technique [10,11]. Forced expiratory volume in the first 0.5 seconds (FEV0.5) and
forced expiratory flow at 50% of expiration (FEF50) were calibrated for gestational age at birth,
sex, height, and weight.
Spirometry. Spirometry was performed half-yearly between age 5 and 7 years and at 13
years using a MasterScope Pneumoscreen spirometer (Erich Jaeger, Wu¨rzburg, Germany)
[17]. Forced expiratory volume in the first second (FEV1) and maximal mid-expiratory flow
(MMEF) were calibrated for height, sex, and age.
To compare the neonatal FEV0.5 and FEF50 with FEV1 and MMEF data from later in child-
hood, the measurements were z-scored based on children never developing asthma and are
subsequently referred to as FEVz and MMEFz.
Whole body plethysmography. Whole body plethysmography was performed half-yearly
between age 3 and 7 years and at 13 years using a MasterScreen sealed bodybox (Erich Jaeger,
Wu¨rzburg, Germany). Measurements were obtained during tidal breathing using a mouth-
piece [18]. Specific airway resistance (sRaw) was calibrated for height, sex, and age; logarithmi-
cally transformed to achieve normal distribution of the data; and subsequently z-scored
(sRawz).
Bronchial reversibility
Bronchial reversibility was measured at age 3, 5, 7, and 13 years by whole body plethysmogra-
phy and at 5, 7, and 13 years by spirometry as the relative change from baseline 15 minutes
after inhalation of β2-agonist. At age 3–7 years, terbutaline, 500 μg (2 × 250 μg) pMDI (Brica-
nyl, AstraZeneca, Cambridge, UK) was delivered via a metal spacer (Nebuchamber, AstraZe-
neca, Cambridge, UK). At 13 years, we used salbutamol, 400 μg (2 × 200 μg) from a discus DPI
(Ventoline, GlaxoSmithKline Pharma, Middlesex, UK).
Bronchial reactivity
Methacholine challenge in neonates. Baseline FEV0.5 was measured after a saline inhala-
tion and following subsequent inhalations of methacholine in quadrupling dose steps from
0.04 to 16.67 μmol/l delivered by a dosimeter attached to a nebulizer (SPIRA 08 TSM 133,
Respiratory Care Center, Ha¨meenlinna, Finland) [10,11]. Bronchial reactivity was assessed
from repeated measurements of FEV0.5 and continuous transcutaneous oxygen pressure
(PtcO2) (TCM3, Radiometer, Copenhagen, Denmark) [10,11].
Methacholine challenge in school age children. Methacholine challenge in school-age
children was performed at 7 and 13 years, measuring FEV1 after a saline inhalation and after
subsequent inhalations of methacholine in quadrupling dose steps from 0.06 to 29.72 μmol/l
(SPIRA 08 TSM 133, Respiratory Care Center, Ha¨meenlinna, Finland).
Bronchial reactivity to methacholine in neonates and school-age children was estimated
from dose–response curves fitted with a logistic function as the provocative dose of methacho-
line producing a 15% decrease in PtcO2 (PD15) in the neonates, according to our previous sen-
sitivity analysis in the cohort [11], and as the provocative dose of methacholine producing a
20% decrease in FEV1 (PD20) at age 7 and 13 years, according to the ATS/ERS guidelines [19].
To enable comparison of the assessments, PD15 and PD20 were logarithmically transformed to
achieve normal distribution of the data, were z-scored, and are subsequently referred to as
PDz.
Lung function development in children with asthma
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Cold dry air challenge. Cold dry air (−18˚C) was delivered by a respiratory heat exchange
system (Erich Jaeger, Wu¨rzburg, Germany) with an animated computer program guiding the
child to hyperventilate at a level corresponding to 1 l/min/kg bodyweight for 4 minutes using a
facemask with a mouthpiece [20]. Bronchial reactivity was determined as the change from
baseline in sRaw at 4 and 6 years and in FEV1 and MMEF at 6 years.
Exercise challenge. At 7 years, the child exercised on a motor-driven treadmill for at least
4 minutes with a pulse rate >80% of the maximal pulse [19] breathing fully dehumidified
atmospheric air through a facemask (Hans Rudolph, Kansas City, MO, US). Spirometry was
performed before, and 1, 3, 5, 10, and 15 minutes after exercise using the maximum percentage
decline in FEV1 from baseline within 10 minutes after exercise as the outcome.
We excluded lung function measurements in children with respiratory tract symptoms in
the preceding week and if β2-agonists had been used within the preceding 12 hours. Bronchial
challenge test results were excluded if the child had a respiratory infection in the preceding 3
weeks [21].
Monitoring of lung symptoms
The parents were taught to recognize troublesome lung symptoms including noisy breathing
(wheezing or whistling sounds), breathlessness, shortness of breath, and persistent coughing at
a session at the research unit. They subsequently recorded their child’s troublesome lung
symptoms, i.e., symptoms significantly affecting the well-being of their child, in a daily diary
as a composite score (yes/no) from age 1 month to 7 years. They were requested to bring the
child to the COPSAC clinic at each episode of 3 consecutive days with symptoms for examina-
tion and verification of the symptoms by the COPSAC pediatricians [2,22]. If the child was
diagnosed with asthma, the diary recording of lung symptoms was continued beyond age 7.
Asthma diagnosis
Age 1 month–7 years. Asthma was diagnosed according to a predefined validated quanti-
tative diary-based algorithm [22]. If the child experienced 5 episodes of troublesome lung
symptoms within 6 months, daily symptoms for 4 weeks, or acute severe symptoms requiring
hospitalization, high-dose ICS, or systemic corticosteroids, then a 3-month course of budeso-
nide 200 μg bid (Spirocort, AstraZeneca, Cambridge, UK) was prescribed, and the child was
examined by a chest X-ray and a sweat chloride test to exclude other chronic lung disorders.
Asthma was diagnosed in children relapsing after ICS withdrawal within the following year,
defined as either 2 episodes within 3 months or 2 consecutive weeks with symptoms, which
resulted in a 6-month course of ICS and an additional 12-month course at subsequent relapses.
Remission was defined as the child being without symptoms and treatment for 1 year.
After age 7 years. Children with troublesome lung symptoms after age 7 years were pre-
scribed inhaled as-needed β2-agonist (terbutaline 250 μg; Bricanyl, AstraZeneca, Cambridge,
UK). If β2-agonist was needed more than 2 days per week and not only in relation to scheduled
physical activity, the child was prescribed a 3-month course of ICS (budesonide 400 μg/day
[2 × 200 μg]; Spirocort, AstraZeneca, Cambridge, UK) and subsequently followed the same
diagnostic procedure for asthma as described above. At the 13-year follow-up visit, the Danish
National Medicine Registry was accessed and screened for any asthma drug prescriptions
from age 7 to 13 years.
Only children attending the clinic at least once at age 0.5–4 years and at age 4–7 years or 13
years were included in the analyses.
Lung function development in children with asthma
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Allergen sensitization
Allergen sensitization towards 10 aeroallergens—birch, grass, mugwort, horse, dog, cat, Der-
matophagoides pteronyssinus, D. farinae, Cladosporium herbarum, and Alternaria alternata—
was determined at age 13 years by skin prick test [23] and by measuring blood levels of specific
IgE [24]. Allergic sensitization was defined as any wheal> 3 mm and/or any specific IgE
value� 0.35 kU/A.
Description of baseline characteristics of the cohort, including pre-, peri- and postnatal fac-
tors is provided in S1 Text.
Statistical analyses
Baseline characteristics of included versus excluded children were compared using Fisher’s
exact test, Student’s t test, and Wilcoxon 2-sample test.
The relationship between development of FEVz, MMEFz, sRawz, and PDz in the first 13
years of life and asthma status was analyzed with mixed models taking repeated participant
measurements into account. The statistic extracted from these mixed models was the fixed
effect of group, i.e., asthma versus no asthma. To test the effect of the normalization of the
lung function measurements, which was done to enable comparison of measurements con-
ducted at varying ages, we also ran the analyses with raw, untransformed data and subse-
quently investigated the normal distribution of the residuals from the different models with
Q-Q plots.
The cold dry air challenge by spirometry (6 years) and exercise challenge (7 years) were
only performed once for each child, and the cross-sectional difference in these measures
between children with asthma and without asthma was analyzed by Student’s t test comparison
of means.
We subsequently investigated whether development of FEVz, MMEFz, sRawz, and PDz
prior to onset of asthma was different from their development in children never developing
asthma. This was done in mixed models comparing FEVz, MMEFz, sRawz, and PDz measure-
ments obtained before diagnosis in children developing asthma with measurements in chil-
dren never developing asthma, evaluating the fixed effect of group, i.e., asthma versus no
asthma. As an ancillary analysis, we also investigated by t tests whether neonatal FEV0.5, FEF50,
and PD15 were different in neonates who subsequently developed asthma versus neonates who
did not develop asthma.
The effect of duration of asthma in the first 13 years of life on lung function development,
i.e., whether lung function declined over time with increasing disease length, was investigated
by calculating the duration of symptomatic disease preceding each lung function measure-
ment. The mixed models used for this analysis were adjusted for time since remission and esti-
mated the slope of the lung function during the period with asthma. The statistic extracted
from these mixed models was the fixed effect of time, i.e., disease length in the observation
period. To further investigate whether asthma status affected measures of FEVz, MMEFz,
sRawz, and PDz over time, age at measurement was included in the analyses as an interaction
term.
Finally, lung function development after remission of asthma was analyzed in mixed mod-
els by evaluating the change over time in FEVz, MMEFz, sRawz, and PDz after remission, evalu-
ating the fixed effect of time since remission.
As post hoc analyses, we investigated development of FEVz, MMEFz, sRawz, and PDz in
children with remission of asthma, i.e., early-transient symptoms, compared to children with
persistent symptoms and children never developing asthma. We also investigated development
of lung function in children with asthma who had specific allergen sensitization at age 13 year
Lung function development in children with asthma
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compared to children with asthma without sensitization. These post hoc analyses were done to
investigate whether there were specific lung function trajectories in different wheeze pheno-
types and whether development of atopy influenced the trajectories. The analyses were done
with mixed models, evaluating the fixed effect of wheeze phenotype and sensitization status.
The effect of missing observations for longitudinal values for FEVz, MMEFz, sRawz, and
PDz was investigated by multiple imputation (for details see S1 Text).
All analyses were performed in R with the package lme4 (version 1.1.14) [25] for linear
mixed models as well as the package mice (version 3.3.0). All estimates are presented with 95%
confidence intervals; p-values < 0.05 were considered significant. The graphical presentations
of the results were made with ggplot2 (version 3.0.0), and the longitudinal curves of FEVz,
MMEFz, and sRawz development were smoothed with loess regression function.
The data are available in S1 Data.
Results
Of the 411 children enrolled at 1 month of age in COPSAC2000, follow-up to age 13 was avail-
able for 367 (89%). The number of children ever versus never developing asthma in their first
13 years of life was 97 (27%) versus 270 (73%), respectively (Fig 1). A total of 54 (56%) children
remitted before age 13 years; 14 (14%) remitted but relapsed later during childhood. Median
age at diagnosis was 2.0 years (IQR 1.2–5.7), median remission age was 6.2 years (IQR 4.2–
7.8), and median duration of asthma was 4.0 years (IQR 2.2–5.3). The mean age of the mother
at the birth of the child was 30.0 years, and 39% of the children had older siblings. There were
no significant differences in baseline characteristics between included and excluded children
(Table 1).
Lung function development in relation to asthma status
The development of FEVz from age 1 month to 13 years in children ever versus never diag-
nosed with asthma in this period is depicted in Fig 2A, illustrating that children developing
asthma already had reduced FEVz as neonates, which persisted until age 13 years as a stable
trait without progression or attenuation during childhood (z-score difference, −0.31 [95% CI
−0.47; −0.15], p< 0.001). The development of MMEFz was similar to that of FEVz (Fig 2B) (z-
score difference, −0.44 [95% CI −0.60; −0.27], p< 0.001). sRawz measurements from age 3 to
13 years showed increased sRaw from age 3 years among children ever versus never developing
asthma, which was sustained till age 13 years without progression or attenuation (Fig 2C) (z-
score difference, +0.40 [95% CI +0.24; +0.56], p< 0.001). Finally, bronchial reactivity to
methacholine (PDz) was persistently increased from age 1 month until age 13 years in children
ever versus never diagnosed with asthma in that period (Fig 2D) (i.e., reduced PDz; z-score dif-
ference, −0.40 [95% CI −0.58; −0.22], p< 0.001) (Table 2). A sensitivity analysis utilizing the
raw, untransformed data showed similar results (Table A in S1 Text). Furthermore, transform-
ing the data led to more normalized residuals (Fig A in S1 Text). Finally, analyses using multi-
ple imputation also showed the same differences in lung function development in children
ever versus never diagnosed with asthma; although the effect estimates were slightly attenu-
ated, the results remained significant (Table B in S1 Text).
In order to test whether the relationship between lung function development and asthma
status varied with age, we introduced the interaction term asthma status × age at measurement
in the models. This analysis showed that there was no interaction between asthma status and
age for lung function measurement (Table C in S1 Text), suggesting that these are predeter-
mined traits established in early life and stable throughout childhood. An ancillary analysis of
neonatal FEV0.5, FEF50, and PD15 showed significantly decreased forced flows and increased
Lung function development in children with asthma
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Fig 1. Flowchart of included children.
https://doi.org/10.1371/journal.pmed.1002722.g001
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reactivity to methacholine in neonates developing asthma within their first 13 years of life
compared to neonates never diagnosed with asthma (Table D in S1 Text).
Children who developed asthma during the first 13 years of life compared to children never
developing asthma also had increased bronchodilator response (absolute difference: FEV1,
+3% [95% CI +2%; +4%], p< 0.001; MMEF, +6% [95% CI 0%; 12%], p = 0.04; sRaw, −4%
[95% CI −6%; −2%], p< 0.001), reduced post-bronchodilator z-scores for FEV1 (−0.16 [95%
CI −0.34; 0.01], p = 0.07) and MMEF (−0.35 [95% CI −0.54; −0.16], p< 0.001), and increased
post-bronchodilator z-score for sRaw (+0.22 [95% CI +0.06; +0.38], p = 0.007).
Reactivity to cold dry air was increased among children ever versus never having asthma
(absolute difference: FEV1, −4% [95% CI −7%; −1%], p = 0.007; MMEF, −8% [95% CI −15%;
−1%], p = 0.03; and sRaw, +9% [95% CI +5%; +13%], p< 0.001). Additionally, children ever
versus never diagnosed with asthma experienced a significantly larger drop in FEV1 after exer-
cise challenge at age 7 years (absolute difference: FEV1, −4% [95% CI −7%; −1%], p = 0.02)
(Table 2).
Table 1. Baseline characteristics.
Characteristic Included children (N = 367) Excluded children (N = 44) p-Value
Prenatal factors
Boys, n/N (%)� 182/367 (50%) 21/44 (48%) 0.87
17q21 risk genotype1, n/N (%)� 103/361 (29%) 11/32 (34%) 0.54
CDHR3 risk genotype2, n/N (%)� 106/337 (31%) 7/28 (25%) 0.53
Filaggrin risk genotype3, n/N (%)� 44/363 (12%) 5/32 (16%) 0.57
Paternal asthma, n/N (%)� 54/358 (15%) 3/43 (7%) 0.17
Maternal smoking in third trimester, n/N (%)� 53/367 (14%) 10/44 (23%) 0.18
Perinatal factors
Gestational age, mean (IQR)�� 40 weeks (39; 41) 40 weeks (39; 41) 0.71
Maternal age at birth, mean (IQR)�� 30.0 years (26.7; 33.2) 29.8 years (26.1; 33.7) 0.79
Cesarean section, n/N (%)� 80/367 (22%) 7/44 (16%) 0.44
Birth weight, mean (IQR)�� 3.52 kg (3.20; 3.82) 3.52 kg (3.31; 3.79) 0.93
Birth length, mean (IQR)�� 52.3 cm (51.0; 54.0) 52.4 cm (51.8; 53.3) 0.76
Postnatal factors
Social circumstances, mean (SD)�� 0.01 (1.00), N = 356 −0.19 (0.98), N = 26 0.30
Older sibling(s), n/N (%)� 139/358 (39%) 12/29 (41%) 0.84
Days of solely breastfeeding, median (IQR)��� 122 (90; 155), N = 354 110 (14; 132), N = 13 0.26
Pets during first year, n/N (%)� 92/360 (26%) 12/35 (34%) 0.31
Age at start in daycare, median (IQR)��� 12 months (8; 14), N = 367 13 months (8; 18), N = 34 0.33
Nicotine in hair at 3 years, GM (95% CI)�� 0.37 ng (0.31; 0.44), N = 309 0.23 ng (0.08; 0.61), N = 11 0.31
Weight at 13 years, mean (IQR)�� 49.2 kg (42.0; 55.1), N = 341 54.2 kg (47.0; 57.2), N = 4 0.46
Height at 13 years, mean (IQR)�� 160.3 cm (154.3; 165.6), N = 341 162.4 cm (155.8; 165.9), N = 4 0.68
�Fisher’s exact test.
��Student’s t test.
���Wilcoxon 2-sample test.
1 Homozygous for the rs7216389 asthma risk allele (T).
2Hetero- or homozygous for the rs6967330 asthma risk allele (A).
3Mutations in R501X, 2282del4, R2447X, and/or S3247X in the filaggrin coding gene.
GM, geometric mean.
https://doi.org/10.1371/journal.pmed.1002722.t001
Lung function development in children with asthma
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Lung function development in relation to debut, duration, and remission
of asthma
Children who developed asthma showed significantly increased airway obstruction and bron-
chial reactivity before symptom debut compared to children never developing asthma (FEVz,
Fig 2. Development of z-scored measures of lung function and bronchial reactivity from 1 month to 13 years. z-Scores for (A)
forced expiratory volume (FEVz), (B) maximal mid-expiratory flow (MMEFz), (C) specific airway resistance (sRawz), and (D)
provocative dose of methacholine (PDz). Dashed lines represent 95% confidence intervals; grey triangles indicate timing of
measurements. The vertical bars in (D) indicate the exact distribution in terms of age of sampling of the raw data.
https://doi.org/10.1371/journal.pmed.1002722.g002
Table 2. Lung function and bronchial reactivity in relation to asthma at age 1 month to 13 years.
Measure Asthma N Mean Difference (95% CI) p-Value
FEV
FEVz z-score# Never 270 0.00 Reference <0.001
Ever 97 −0.33 −0.31 (−0.47; −0.15)
FEVz z-score after β2-agonist# Never 261 0.00 Reference 0.07
Ever 94 −0.20 −0.16 (−0.34; +0.01)
Percent change in FEV1 after β2-agonist
# Never 261 +3% Reference <0.001
Ever 94 +6% +3% (+2%; +4%)
Percent change in FEV1 after cold dry air
## Never 182 −3% Reference 0.007
Ever 69 −7% −4% (−7%; −1%)
Percent change in FEV1 after exercise
## Never 210 −8% Reference 0.02
Ever 78 −12% −4% (−7%; −1%)
MMEF
MMEFz z-score# Never 269 0.00 Reference <0.001
Ever 97 −0.46 −0.44 (−0.60; −0.27)
MMEFz z-score after β2-agonist# Never 261 0.00 Reference <0.001
Ever 94 −0.38 −0.35 (−0.54; −0.16)
Percent change in MMEF after β2-agonist
# Never 261 +21% Reference 0.04
Ever 94 +28% +6% (0%; +12%)
Percent change in MMEF after cold dry air## Never 178 −4% Reference 0.03
Ever 68 −12% −8% (−15%; −1%)
sRaw
sRawz z-score# Never 263 0.00 Reference <0.001
Ever 94 +0.41 +0.40 (+0.24; +0.56)
sRawz z-score after β2-agonist# Never 261 0.00 Reference 0.007
Ever 93 +0.25 +0.22 (+0.06; +0.38)
Percent change in sRaw after β2-agonist
# Never 261 −19% Reference <0.001
Ever 93 −23% −4% (−6%; −2%)
Percent change in sRaw after cold dry air# Never 215 +8% Reference <0.001
Ever 76 +16% +9% (+5%; +13%)
PD
PDz z-score# Never 267 0.00 Reference <0.001
Ever 95 −0.39 −0.40 (−0.58; −0.22)
Significant p-values in bold.
#Mixed models.
##Student’s t test.
FEV, forced expiratory volume; MMEF, maximal mid-expiratory flow; PD, provocative dose of methacholine; sRaw, specific airway resistance.
https://doi.org/10.1371/journal.pmed.1002722.t002
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−0.29 [95% CI −0.49; −0.09], p = 0.004; MMEFz, −0.40 [95% CI −0.60; −0.20], p< 0.001;
sRawz, +0.33 [95% CI +0.10; +0.57], p = 0.006; and PDz, −0.35 [95% CI −0.59; −0.12], p =
0.003).
The airway obstruction and increased bronchial reactivity in children developing asthma
were independent of disease duration (change per year: FEVz, −0.01 [95% CI −0.07; +0.06],
p = 0.82; MMEFz, −0.01 [95% CI −0.05; +0.03], p = 0.68; sRawz, −0.02 [95% CI −0.06; +0.03],
p = 0.43; and PDz, −0.04 [95% CI −0.10; +0.03], p = 0.27). Furthermore, the airway obstruction
and increased bronchial reactivity did not attenuate after remission (change per year: FEVz,
+0.02 [95% CI −0.03; +0.06], p = 0.44; MMEFz, −0.00 [95% CI −0.04; +0.04], p = 0.98; sRawz,
+0.01 [95% CI −0.03; +0.06], p = 0.54; and PDz, +0.00 [95% CI −0.07; +0.08], p = 0.92)
(Table 3).
Lung function development in relation to transient versus persistent
asthmatic symptoms
Among the 97 children who fulfilled the diagnostic criteria for asthma, 54 children had a transient
phenotype and remitted before age 13 years, whereas the remaining 43 children had persistent
asthmatic symptoms requiring continued ICS by age 13 years. Lung function development in chil-
dren with transient asthmatic symptoms compared to children never diagnosed with asthma
showed reduced FEVz (z-score difference, −0.30 [95% CI −0.51; −0.08], p = 0.008) and reduced
MMEFZ (−0.36 [95% CI −0.59; −0.14], p = 0.002) from age 1 month to 13 years, and increased
sRawz from age 3 years to 13 years (+0.27 [95% CI +0.06; +0.48], p = 0.01). PDz was reduced
among transiently asthmatic versus healthy children, i.e., indicating increased airway reactivity,
but this difference was not significant (−0.15 [95% CI −0.39; +0.09], p = 0.23).
There were no differences in development of FEVz, MMEFz, or sRawz among children with
transient versus persistent asthmatic symptoms, whereas children with transient compared to
Table 3. Lung function development in relation to asthma debut, duration, and remission.
Measure N Difference (95% CI) p-Value
z-Score before diagnosis relative to children never developing asthma
FEVz before diagnosis
# 93 −0.29 (−0.49; −0.09) 0.004
MMEFz before diagnosis
# 93 −0.40 (−0.60; −0.20) <0.001
sRawz before diagnosis
# 32 +0.33 (+0.10; +0.57) 0.006
PDz before diagnosis
# 87 −0.35 (−0.59; −0.12) 0.003
Change in z-score per year duration of asthma
FEVz development
# 92 +0.02 (−0.02; +0.07) 0.36
MMEFz development
# 92 −0.01 (−0.05; +0.03) 0.68
sRawz development
# 89 −0.02 (−0.06; +0.03) 0.43
PDz development
# 87 −0.04 (−0.10; +0.03) 0.27
Change in z-score per year after remission of asthma
FEVz development
# 54 +0.02 (−0.03; +0.06) 0.44
MMEFz development
# 54 −0.00 (−0.04; +0.04) 0.98
sRawz development
# 51 +0.01 (−0.03; +0.06) 0.54
PDz development
# 48 +0.00 (−0.07; +0.08) 0.92
Significant p-values in bold.
#Mixed models.
FEV, forced expiratory volume; MMEF, maximal mid-expiratory flow; PD, provocative dose of methacholine; sRaw,
specific airway resistance.
https://doi.org/10.1371/journal.pmed.1002722.t003
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persistent symptoms had less airway reactivity to methacholine, i.e., higher PDz (+0.48 [95%
CI +0.15; +0.80], p = 0.004) (Fig 3; Table E in S1 Text).
Lung function development in relation to allergic sensitization
At age 13 years, 157 (52%) of 304 tested children had allergic sensitization towards 1 or more
of the tested allergens by either a positive skin prick test and/or elevated blood level of specific
IgE. Sensitization was diagnosed in 109 (49%) of 223 children never developing asthma, 15
(36%) of 42 children with transient asthmatic symptoms, and in 33 (85%) of 39 children with
persistent asthmatic symptoms. Thus, sensitization was more prevalent in children with persis-
tent asthma versus children never developing asthma (chi-squared test, p< 0.001) and in chil-
dren with persistent versus transient asthmatic symptoms (chi-squared test, p< 0.001).
There were no differences in development of FEVz, MMEFz, or sRawz among children who
developed asthma with versus without allergen-specific sensitization to any of the tested aller-
gens, whereas there was a pattern suggesting increased airway reactivity to methacholine
among children with asthma who were sensitized by age 13 years, i.e., lower PDz (−0.34 [95%
CI −0.70; +0.02], p = 0.06) (Table E in S1 Text). Stratifying the analyses on type of allergen as
(1) house dust mite, (2) furred animal (dog, cat, horse), or (3) pollen (birch, grass, mugwort)
showed similar results except that children with asthma and sensitization to pollen had signifi-
cantly lower PDz (Table E in S1 Text).
Discussion
Primary findings
Children developing asthma at any time during the first 13 years of life had airway obstruction
and increased bronchial reactivity that was present at age 1 month without worsening with
increased symptom duration and without improvement after remission. This suggests that
these are inherent and stable traits not caused by inflammation during symptomatic periods
but rather that predispose the child to develop asthmatic symptoms, exaggerated hyperreactiv-
ity, and intermittent airway obstruction.
Strengths and limitations
The primary strength of this study is the thorough single-center close clinical surveillance of a
cohort with a follow-up of 89% till age 13 years. The children were seen for clinical evaluation
and lung function assessment at the age of 1 month and thereafter at least half-yearly until age
7 years and again at 13 years. Until age 7 years, the parents filled daily diary cards describing
the child’s troublesome lung symptoms, thereby diminishing recall bias [26]. Asthma was diag-
nosed and treated by the COPSAC pediatricians only according to a predetermined algorithm
with a conservative definition based on symptom load and response to and relapse after a stan-
dard dose and period of ICS [22], thus avoiding diagnostic heterogeneity. Children with
asthma were seen for scheduled 3-monthly visits and for unscheduled acute visits during wors-
ening of symptoms and continued daily symptom diary recording beyond age 7 years if symp-
toms persisted.
The diagnostic algorithm for asthma, which was based on quantitative symptom assess-
ments verified at scheduled and acute care visits to the research unit and response to ICS treat-
ment, could identify asthmatic children with transient, recurrent viral-induced wheeze and
children with a persistent phenotype with or without atopy. This is apparent as approximately
half of the children diagnosed according to the algorithm had transient symptoms and remit-
ted before age 13 years. The median age at diagnosis was 2 years, implying that a large
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proportion of the cases were children whose initial episode of wheezing was related to an infec-
tion, but half of these children had ICS-dependent asthma by age 13 years. Importantly, not all
children with asthma will respond to ICS initially, and because lack of ICS response cannot
exclude asthma, we excluded other chronic lung diseases by means of chest X-ray and a sweat
chloride test for cystic fibrosis.
A significant advantage of the study is the longitudinal repetitive lung function assessments
performed at 11 time points during childhood by means of spirometry and plethysmography
as well as bronchial reactivity to cold dry air, exercise, and methacholine challenge in accor-
dance with recognized guidelines [17–20,27]. We did most measurements in the age range
from 3 to 7 years; therefore, the shape of the curves is likely to be influenced by the readings at
1 month and 13 years. Still, the birth cohort design assured that lung function was assessed (1)
before the debut of symptoms and asthma diagnosis, (2) repeatedly every 6 months in children
with and without asthma, and (3) after remission in children outgrowing their asthma. This
allowed us to scrutinize how lung function trajectories develop in children with asthma during
childhood and how they are affected by duration and remission of symptoms. Our interaction
analyses showed no evidence of age influence on the difference in lung function development
in children with versus without asthma, but the low numbers in our cohort may preclude us
from detecting subtle differences with age.
It is a strength of our study that neonatal spirometry was performed using the raised vol-
ume rapid thoracoabdominal compression technique, providing volume-anchored measure-
ments [10], which makes its results comparable with the forced volumes obtained by
spirometry later in childhood. This is an important difference compared to previous studies of
neonatal lung function in relation to asthma and lung function development during child-
hood, which used non-volume-anchored methods [12–14,28]. Assessment of tidal breathing
patterns is one such method, which is less sensitive, has high intra-individual variability
[29,30], and yields results not associated with volume-anchored measurements later in child-
hood [13].
One previous study of 95 children investigated airway reactivity from age 1 month through-
out childhood, but used a non-volume-anchored assessment of histamine challenge that did
not correlate with the FEV1-based histamine challenge results at school age, highlighting the
same problem of using different approaches to determine neonatal lung function and lung
function later in childhood [12,31,32].
The limitations of our study are the relatively small sample size, the limited ethnic variation,
and the high-risk nature of the COPSAC2000 cohort, which hamper the generalizability of the
findings. However, mothers without asthma might be reluctant to have their neonates investi-
gated so thoroughly by lung function testing during sedation. Children of asthmatic mothers
are a priori at higher risk of asthma and may experience more severe symptoms and have
poorer lung function. However, the children not developing asthma also had asthmatic moth-
ers, and we do not expect the relationship between symptoms and lung function development
to be different due to asthma predisposition.
We observed z-score differences in lung function trajectories with magnitudes between 0.3
and 0.4 in children who developed asthma compared to children not developing asthma. This
overall difference in lung function development is not in the abnormal range, which would be
less than −2 z-scores, but it should be kept in mind that we excluded measurements obtained
Fig 3. Development of z-scored measures of lung function and bronchial reactivity from 1 month to 13 years in children with
transient asthma, children with persistent asthma, and children never developing asthma. z-Scores for (A) forced expiratory volume
(FEVz), (B) maximal mid-expiratory flow (MMEFz), (C) specific airway resistance (sRawz), and (D) provocative dose of methacholine
(PDz). Dashed lines represent 95% confidence intervals; grey triangles indicate timing of measurements.
https://doi.org/10.1371/journal.pmed.1002722.g003
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during exacerbations, which may have diminished the overall difference between children
with versus without asthma.
Interpretation
We found that airway obstruction and bronchial hyperreactivity related to asthma are fixed
traits from age 1 month to age 13 years, without further deterioration from disease duration or
improvement after symptom remission. These findings have important implications for our
understanding of the underlying pathology, indicating that the symptomatic phases of child-
hood asthma are not causing the airway obstruction and bronchial hyperreactivity typical of
asthma. Instead, we propose that airway obstruction and bronchial hyperreactivity are inher-
ent traits that increase the risk of developing airway inflammation and asthmatic symptoms
during childhood. This may explain the lack of effect from early intervention with ICS, which
was unable to change the natural course of asthma with respect to both symptom burden and
lung function development [2–6].
Our findings are consistent with a follow-up study of children diagnosed with asthma at
age 9 years showing that individuals still experiencing symptoms at age 26 years had stable air-
way obstruction and bronchial reactivity without any progression from the assessments at age
9 years [33]. In addition, a 22-year follow-up of a cohort of 40-year-old adults also showed that
reduced lung function at cohort inception remained stable over time [34]. Together with the
present study, this suggests that airflow obstruction and bronchial hyperreactivity are inherent
and stable deficits measurable already at age 1 month. Thus, even though lung function fluctu-
ates with symptom load and anti-inflammatory treatment over time [35], the lung function
trajectory is a static characteristic that might contribute to asthmatic symptoms, exaggerated
bronchial reactivity, and intermittent airway obstruction.
Our findings contrast with those of a recent study investigating the development of lung
function in children with asthma into adulthood [36], which suggested that the majority of
children with asthma (75%) had an abnormal pattern of reduced growth and/or early decline
in lung function, i.e., not a stable trait. This difference may be due to the fact that the study
only enrolled 5- to 12-year-old children with uncontrolled chronic asthma (symptoms >2
days/week) and severe bronchial hyperreactivity at baseline (>20% drop in FEV1 after metha-
choline challenge), resembling a minority population of the most severely affected children.
Even more important, the participants with reduced growth in lung function already had sig-
nificantly lower lung function at enrollment, suggesting that their lung function trajectories
may be a static characteristic established in early childhood. In line with our findings, another
recent study demonstrated increased airway resistance among children with persistent wheeze,
which tracked from early to late childhood [37].
We suggest that the propensity to develop asthmatic symptoms due to intrinsic and extrin-
sic factors is increased by underlying inherent airflow obstruction and bronchial hyperreactiv-
ity, which are stable traits without progression due to triggering factors or increased symptom
duration. On the other hand, we and other groups have shown that allergic sensitization after
the age of 6 years, but not earlier in childhood, is associated with an increased risk of develop-
ing asthma [38,39], with different risks for different allergens [40]. This raises the possibility
that development of allergy may have a deteriorating effect on the lung function trajectory.
However, our data in general argue against such a hypothesis as development of airflow
obstruction as measured by FEVz, MMEFz, and sRawz among children with asthma was inde-
pendent of allergic sensitization at age 13 years, whilst there was a non-significant suggestion
of increased airway reactivity among sensitized asthmatic individuals that was significant in
the subgroup with sensitization to pollens, which were the most common allergens in our
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cohort. These findings are in line with a study of 1,719 15-year-old participants in the German
GINIplus birth cohort, which did not show any associations between sensitization and spiro-
metric indices in children with asthma [41], but are in contrast to the American TENOR study
of 1,261 children aged 6 to 17 years with severe or difficult-to-treat asthma, which showed an
association between increased airflow limitation and higher IgE levels [42]. Importantly, both
these studies were cross-sectional analyses; a longitudinal study showed that development of
lung function from age 1 month until 11 years was unaffected by atopy [13].
Interestingly, we found that all children who fulfilled the diagnostic criteria for asthma
compared to children never diagnosed with asthma had increased airway obstruction, i.e.,
reduced FEVz and MMEFz (age 1 month to 13 years) and increased sRawz (age 3 years to 13
years), irrespective of remission of symptoms or not. Thus, fixed airway obstruction was
apparent in children with both a transient and a persistent phenotype and without differences
in development of FEVz, MMEFz, and sRawz between the phenotypes, whereas bronchial reac-
tivity to methacholine (PDz) was more pronounced in children with persistent as opposed to
transient symptoms. This suggests that airway reactivity in children with transient asthmatic
symptoms declines with airway growth through childhood, whereas reduced forced flows and
increased airway resistance are fixed traits among children with the transient phenotype, irre-
spective of airway growth. These findings align with findings from longitudinal lung function
measurements from birth until age 16 years in the Tucson Children’s Respiratory Study [43]
and from age 3 years until age 11 years in the Manchester Asthma and Allergy Study [37],
showing that children with persistent wheeze compared to never wheeze had increased and
fixed airway obstruction, which was also apparent for children with early-transient viral-
induced wheeze even though they outgrew their symptoms. Furthermore, a smaller Australian
study from Perth also showed a suggestion of reduced lung function from birth until age 11
years in children with persistent wheeze, whereas no reduction of lung function was observed
for other phenotypes of wheeze [12]. Overall, these studies together with our study suggest a
common underlying lung function deficit driving early-transient, typically viral-induced
symptoms and persistent symptoms, typically triggered by allergens, pollutants, or exercise.
Conclusion
In this study we observed that airway obstruction and increased bronchial reactivity associated
with childhood asthma were established already at age 1 month, without further deterioration
into early adolescence and without relation to asthma symptom duration or remission. This
suggests that these chronic deficits are not the result of childhood asthma, but may instead
contribute to asthma pathogenesis by increasing the risk of symptoms, exaggerated hyperreac-
tivity, and airway obstruction, implying that preventive measures for improved lung health
should focus on the pre- or perinatal period.
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